Corey Goodman, venBio

Corey Good­man mar­shals $105M mega-round for his CD47 up­start, look­ing to break new ground in PhII

Corey Good­man has put an­oth­er notch on his ven­ture belt, ring­ing up a $105 mil­lion mega-round for his CD47 start­up ALX On­col­o­gy.

Fu­el­ing a start­up backed by his group at ven­BIO, the new mon­ey will go to a slate of mid-stage stud­ies to test the the­o­ry that his biotech’s ALX 148 could be a game-chang­er in the CD47 are­na. And that could be nice win­dow dress­ing for a com­pa­ny that may be look­ing to go the IPO route.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA